Clinical usefulness of monitoring cytomegalovirus-specific immunity by quantiferon-CMV in pediatric allogeneic hematopoietic stem cell transplantation recipients

Annals of Laboratory Medicine

Volumn 37, Issue 3, 2017, Pages 277-281

  Lee, Sae Mi ^a   Kim, Yae Jean ^a   Yoo, Keon Hee ^a   Sung, Ki Woong ^a   Koo, Hong Hoe ^a   Kang, Eun Suk ^a  

^a Samsung Medical Center   (South Korea)

Author keywords

Cytomegalovirus; Pediatric hematopoietic stem cell transplantation; Quantiferon CMV; T cell immunity

Indexed keywords

CYTOMEGALOVIRUS MATRIX PROTEIN 65KDA; GAMMA INTERFERON; MATRIX PROTEIN; PHOSPHOPROTEIN;

ALLOTRANSPLANTATION; CHILD; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DIRECT FLUORESCENT ANTIBODY TECHNIQUE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; PILOT STUDY; PROSPECTIVE STUDY; RECURRENT DISEASE; T LYMPHOCYTE; VIROLOGY;

CHILD; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERFERON-GAMMA; PHOSPHOPROTEINS; PILOT PROJECTS; PROSPECTIVE STUDIES; RECURRENCE; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; VIRAL MATRIX PROTEINS;

EID: 85015579262     PISSN: 22343806     EISSN: 22343814     Source Type: Journal    
DOI: 10.3343/alm.2017.37.3.277     Document Type: Article

References (17)

1. Hebart H and Einsele H. Clinical aspects of CMV infection after stem cell transplantation. Hum Immunol 2004;65:432-6.
2. Castagnola E, Cappelli B, Erba D, Rabagliati A, Lanino E, Dini G. Cytomegalovirus infection after bone marrow transplantation in children. Hum Immunol 2004;65:416-22.
3. Ljungman P. CMV infections after hematopoietic stem cell transplantation. Bone Marrow Transplant 2008;42(Sl):S70-2.
4. Meijer E, Boland GJ, Verdonck LF. Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants. Clin Microbiol Rev 2003;16:647-57.
5. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993;118:173-8.
6. Goodrich JM, Boeckh M, Bowden R. Strategies for the prevention of cytomegalovirus disease after marrow transplantation. Clin Infect Dis 1994; 19:287-98.
7. Boeckh M, Fries B, Nichols WG. Recent advances in the prevention of CMV infection and disease after hematopoietic stem cell transplantation. Pediatr Transplant 2004;8(S5):S19-27.
8. Crough T and Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev 2009;22:76-98.
9. Harari A, Zimmerli SC, Pantaleo G. Cytomegalovirus (CMV)-specific cellular immune responses. Hum Immunol 2004;65:500-6.
10. Avetisyan G, Aschan J, Hägglund H, Ringdén O, Ljungman P. Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT. Bone Marrow Transplant 2007;40:865-9.
11. Walker S, Fazou C, Crough T, Holdsworth R, Kiely P, Veale M, et al. Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV. Transpl Infect Dis 2007;9:165-70.
12. Tey SK, Kennedy GA, Cromer D, Davenport MP, Walker S, Jones LI, et al. Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV® assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications. PLoS One 2013;8:e74744.
13. Manuel O, Husain S, Kumar D, Zayas C, Mawhorter S, Levi ME, et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis 2013;56:817-24.
14. Lochmanova A, Lochman I, Tomaskova H, Marsalkova P, Raszka J, Mrazek J, et al. Quantiferon-CMV test in prediction of cytomegalovirus infection after kidney transplantation. Transplant Proc 2010;42:3574-7.
15. Fleming T, Dunne J, Crowley B. Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMVassay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital. J Med Virol 2010;82:433-40.
16. Kumar D, Chernenko S, Moussa G, Cobos I, Manuel O, Preiksaitis J, et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 2009;9:1214-22.
17. Abate D, Cesaro S, Cofano S, Fiscon M, Saldan A, Varotto S, et al. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients. Transplantation 2012;93:536-42.